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Sir,
Mickisch et al (2010) report a comparison of the costs of
managing side effects due to treatment with either sunitinib or
bevacizumab plus interferon, the two presently available standards
of care for the first-line treatment of advanced kidney cancer, in
four European countries, i.e., Germany, UK, France, and Italy.
This analysis is of value for clinical practice given the recent
availability of several molecularly targeted therapies for the
treatment of advanced kidney cancer, including bevacizumab
and sunitinib, which have radically changed the natural history of
the disease. These therapies have made – at least in the vast
majority of cases – this once orphan tumour more likely a chronic
disease. Such relative long-term disease stabilisation is inevitably
accompanied by increasing costs and, even though these new
therapies are usually quite well tolerated, side effects may
nevertheless occur, which leads to the need for further resources
such as extra medical treatment or hospitalisation. As we do not
presently have predictive features that could help us to a priori
select responders to treatments such as bevacizumab and
sunitinib, it is important that one should take into account both
the primary costs of each of these treatments – in some countries
artificially made uniform by regulatory authorities – and also
secondary costs, such as those related to the management of these
therapy-induced side effects.
Mickisch et al used pivotal trial data (Escudier et al, 2007;
Motzer et al, 2007) and financial figures obtained from the
healthcare systems of each of the four countries; a linear decision
analytic model was then used to calculate the cost comparison. The
average cost per patient for the management of grade 3 and 4 side
effects was markedly higher with sunitinib, as compared with
bevacizumab plus interferon. Despite a relevant cost variability
among the four countries, sunitinib treatment led to an average
increase in the costs of treatment, owing to the management of
therapy-related grade 3 and 4 side effects, of 637.5 h (ranging from
418 h for Germany to 972 h for France). Notably, such a difference
could also be considered as an underestimation; indeed, we already
know that lowering the dose of interferon can lead to a reduction
in side effects experienced by patients receiving the bevacizumab–
interferon combination, whereas efficacy seems to be maintained
(Melichar et al, 2008), therefore potentially leading to further
savings. These savings are both in terms of a reduction in the
amount of interferon used, as well as in the resources necessary for
the management of interferon-related side effects.
Moreover, toxicities such as hypothyroidism and cardiotoxicity
may have been grossly underestimated in the sunitinib registrative
trial (Motzer et al, 2007) compared with the levels indicated from
other recent studies of sunitinib (Rini et al, 2007; Chen, 2009;
Torino et al, 2009; Di Lorenzo et al, 2009), whereas the safety
profile of bevacizumab plus interferon does not seem to have
changed so much over time. When considering these additional
facts, the indirect economic advantage of bevacizumab plus
interferon seems to be even more evident and convincing.
In sum, the report by Mickisch et al (2010) highlights that when
deciding the ideal treatment for each given patient affected by
advanced kidney cancer entering our hospitals, we should take
into account economic factors (secondary costs) in addition to the
efficacy and safety profiles of available treatments.
ACKNOWLEDGEMENTS
Galliard Healthcare Communications provided support for
checking the English.
REFERENCES
Chen MH (2009) Cardiac dysfunction induced by novel targeted anticancer
therapy: an emerging issue. Curr Cardiol Rep 11: 167–174
Di Lorenzo G, Autorino R, Bruni G, Cartenı ` G, Ricevuto E,
Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M,
Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido
S (2009) Cardiovascular toxicity following sunitinib therapy in
metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:
1535–1542 Published online 23 February 2010
*Correspondence: Dr C Porta; E-mail: c.porta@smatteo.pv.it
British Journal of Cancer (2010) 102, 1196–1197
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.comEscudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,
Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO,
Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN Trial
investigators. Bevacizumab plus interferon alfa-2a for treatment of
metastatic renal cell carcinoma: a randomised, double-blind phase III
trial. Lancet 370: 2103–2111
Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C,
Chevreau C, Filipek M, Delva R, Sevin E, Negrier S, McKendrick J,
Santoro A, Pisa P, Escudier B (2008) First-line bevacizumab combined
with reduced dose interferon-alpha2a is active in patients with metastatic
renal cell carcinoma. Ann Oncol 19: 1470–1476
Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M (2010)
Costs of managing adverse events in the treatment of first-line metastatic
renal cell carcinoma: bevacizumab in combination with interferon-a2a
compared with sunitinib. Br J Cancer 102: 80–86
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O,
Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM,
Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med 356: 115–124
Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S,
Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with
metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst
99: 81–83
Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic
effect of targeted therapy. Nat Rev Clin Oncol 6: 219–228
Letter to the Editor
1197
British Journal of Cancer (2010) 102(7), 1196–1197 & 2010 Cancer Research UK